CTMC

Activities: Research & Development

Trending Articles

  1. Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
  2. KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
  3. Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
  4. New FAIRY viral assay could 'revolutionise' the response to future pandemics The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
  5. New advice from BOLA and Labtex on cleaning and handling of PTFE products after use The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...

Upcoming event

ISPE Singapore

28-30 August 2024 | Conference and exhibition | Singapore See all

Related Content

Manufacturing

Investing in a manufacturing infrastructure to harness tumour-infiltrating lymphocytes (TILs) for cancer treatment

In this article, Dr Chantale Bernatchez, Director of Process Development at CTMC, highlights the need for a standardised TIL manufacturing process that facilitates co-ordination between labs, clinics and production sites. She emphasises the value of using the lessons learned from implementing CAR-T therapy to streamline the introduction of new TIL treatments to the patients who need them
Subscribe now